Calamos Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37.4M | Sell |
75,388
-2,498
| -3% | -$1.11M | 0.12% | 170 |
|
|
2026
Q1 | $34.8M | Buy |
77,886
+33,917
| +77% | +$15.8M | 0.12% | 189 |
|
|
2025
Q4 | $19.9M | Sell |
43,969
-1,784
| -4% | -$769K | 0.07% | 268 |
|
|
2025
Q3 | $17.9M | Hold |
45,753
| – | – | 0.07% | 297 |
|
|
2025
Q2 | $20.4M | Hold |
45,753
| – | – | 0.08% | 265 |
|
|
2025
Q1 | $22.2M | Buy |
45,753
+509
| +1% | +$237K | 0.1% | 236 |
|
|
2024
Q4 | $18.2M | Hold |
45,244
| – | – | 0.08% | 275 |
|
|
2024
Q3 | $21M | Sell |
45,244
-1,189
| -3% | -$571K | 0.09% | 262 |
|
|
2024
Q2 | $21.8M | Sell |
46,433
-1,691
| -4% | -$734K | 0.1% | 238 |
|
|
2024
Q1 | $20.1M | Sell |
48,124
-21,048
| -30% | -$8.9M | 0.1% | 248 |
|
|
2023
Q4 | $28.1M | Sell |
69,172
-923
| -1% | -$341K | 0.14% | 196 |
|
|
2023
Q3 | $24.4M | Hold |
70,095
| – | – | 0.13% | 204 |
|
|
2023
Q2 | $24.7M | Sell |
70,095
-11,477
| -14% | -$3.87M | 0.12% | 213 |
|
|
2023
Q1 | $25.7M | Sell |
81,572
-10,185
| -11% | -$3.05M | 0.13% | 203 |
|
|
2022
Q4 | $26.5M | Sell |
91,757
-16,171
| -15% | -$4.93M | 0.12% | 209 |
|
|
2022
Q3 | $31.2M | Buy |
107,928
+37
| +0% | +$10.6K | 0.14% | 175 |
|
|
2022
Q2 | $30.4M | Buy |
107,891
+2,904
| +3% | +$777K | 0.13% | 188 |
|
|
2022
Q1 | $27.4M | Buy |
104,987
+13,837
| +15% | +$3.28M | 0.1% | 233 |
|
|
2021
Q4 | $20M | Sell |
91,150
-19,807
| -18% | -$3.85M | 0.07% | 276 |
|
|
2021
Q3 | $20.1M | Sell |
110,957
-17,046
| -13% | -$3.33M | 0.09% | 250 |
|
|
2021
Q2 | $25.8M | Sell |
128,003
-71,266
| -36% | -$14.9M | 0.12% | 205 |
|
|
2021
Q1 | $42.8M | Buy |
199,269
+57,190
| +40% | +$12.6M | 0.23% | 102 |
|
|
2020
Q4 | $33.6M | Sell |
142,079
-4,076
| -3% | -$935K | 0.19% | 137 |
|
|
2020
Q3 | $39.8M | Sell |
146,155
-25,789
| -15% | -$7.11M | 0.26% | 102 |
|
|
2020
Q2 | $49.9M | Buy |
171,944
+57,288
| +50% | +$15.5M | 0.35% | 66 |
|
|
2020
Q1 | $27.3M | Buy |
114,656
+72,931
| +175% | +$16.7M | 0.21% | 140 |
|
|
2019
Q4 | $9.14M | Sell |
41,725
-727
| -2% | -$147K | 0.05% | 370 |
|
|
2019
Q3 | $7.19M | Buy |
42,452
+3,681
| +9% | +$651K | 0.04% | 428 |
|
|
2019
Q2 | $7.11M | Buy |
38,771
+1,928
| +5% | +$337K | 0.04% | 426 |
|
|
2019
Q1 | $6.78M | Buy |
36,843
+408
| +1% | +$75.4K | 0.04% | 393 |
|
|
2018
Q4 | $6.04M | Buy |
36,435
+5,455
| +18% | +$945K | 0.04% | 397 |
|
|
2018
Q3 | $5.97M | Sell |
30,980
-3,148
| -9% | -$561K | 0.03% | 424 |
|
|
2018
Q2 | $5.8M | Buy |
34,128
+4,028
| +13% | +$624K | 0.04% | 406 |
|
|
2018
Q1 | $4.91M | Buy |
30,100
+1,418
| +5% | +$232K | 0.03% | 436 |
|
|
2017
Q4 | $4.3M | Sell |
28,682
-547
| -2% | -$81K | 0.02% | 416 |
|
|
2017
Q3 | $4.44M | Buy |
29,229
+1,022
| +4% | +$154K | 0.03% | 387 |
|
|
2017
Q2 | $3.63M | Buy |
+28,207
| New | +$3.4M | 0.03% | 442 |
|
|
2014
Q1 | – | Sell |
-43,138
| Closed | -$3.21M | – | 667 |
|
|
2013
Q4 | $3.21M | Buy |
+43,138
| New | +$3M | 0.02% | 371 |
|
Other funds holding VRTX
Calamos Advisors's VRTX Position: Q2 2026 in Review
Calamos Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q2 2026, selling an estimated $1.11M and leaving 75,388 shares worth $37.4M. The position accounts for 0.12% of the portfolio, ranked #170.
Calamos Advisors first reported a position in VRTX in Q4 2013 and has held it in 38 quarters since. The position peaked at $49.9M in Q2 2020. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Calamos Advisors held 75,388 shares of Vertex Pharmaceuticals worth $37.4M as of Q2 2026.
- Calamos Advisors sold 2,498 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
- Vertex Pharmaceuticals made up 0.12% of Calamos Advisors's portfolio in Q2 2026, its #170 holding.
- Calamos Advisors first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 38 quarters since.
- Calamos Advisors's Vertex Pharmaceuticals position peaked at $49.9M in Q2 2020.
- 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.